Abbott Laboratories (ABT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abbott Laboratories (ABT) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.79 Billion) by net assets ($51.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abbott Laboratories - Cash Flow Conversion Efficiency Trend (1989–2024)
This chart illustrates how Abbott Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Abbott Laboratories (ABT) total liabilities for a breakdown of total debt and financial obligations.
Abbott Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abbott Laboratories ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock Inc
NYSE:BLK
|
0.038x |
|
Deere & Company
NYSE:DE
|
-0.034x |
|
Deutsche Telekom AG
XETRA:DTE
|
0.117x |
|
Salesforce.com Inc
NYSE:CRM
|
0.092x |
|
Deutsche Telekom AG
F:DTEA
|
0.117x |
|
Union Pacific Corporation
NYSE:UNP
|
0.120x |
|
Airbus Group SE
PA:AIR
|
0.060x |
|
Shopify Inc
TO:SHOP
|
0.055x |
Annual Cash Flow Conversion Efficiency for Abbott Laboratories (1989–2024)
The table below shows the annual cash flow conversion efficiency of Abbott Laboratories from 1989 to 2024. For the full company profile with market capitalisation and key ratios, see Abbott Laboratories (ABT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.90 Billion | $8.56 Billion | 0.179x | -4.46% |
| 2023-12-31 | $38.83 Billion | $7.26 Billion | 0.187x | -27.97% |
| 2022-12-31 | $36.91 Billion | $9.58 Billion | 0.260x | -11.21% |
| 2021-12-31 | $36.02 Billion | $10.53 Billion | 0.292x | +22.13% |
| 2020-12-31 | $33.00 Billion | $7.90 Billion | 0.239x | +22.12% |
| 2019-12-31 | $31.30 Billion | $6.14 Billion | 0.196x | -4.40% |
| 2018-12-31 | $30.72 Billion | $6.30 Billion | 0.205x | +14.49% |
| 2017-12-31 | $31.10 Billion | $5.57 Billion | 0.179x | +28.96% |
| 2016-12-31 | $23.06 Billion | $3.20 Billion | 0.139x | +12.76% |
| 2015-12-31 | $24.08 Billion | $2.97 Billion | 0.123x | -19.04% |
| 2014-12-31 | $24.16 Billion | $3.67 Billion | 0.152x | +15.65% |
| 2013-12-31 | $25.27 Billion | $3.32 Billion | 0.132x | -62.13% |
| 2012-12-31 | $26.81 Billion | $9.31 Billion | 0.347x | -5.02% |
| 2011-12-31 | $24.53 Billion | $8.97 Billion | 0.366x | -1.25% |
| 2010-12-31 | $23.59 Billion | $8.74 Billion | 0.370x | +17.41% |
| 2009-12-31 | $23.06 Billion | $7.28 Billion | 0.315x | -24.92% |
| 2008-12-31 | $17.48 Billion | $7.34 Billion | 0.420x | +44.10% |
| 2007-12-31 | $17.78 Billion | $5.18 Billion | 0.292x | -23.11% |
| 2006-12-31 | $14.05 Billion | $5.33 Billion | 0.379x | +5.64% |
| 2005-12-31 | $14.42 Billion | $5.17 Billion | 0.359x | +16.66% |
| 2004-12-31 | $14.33 Billion | $4.41 Billion | 0.308x | +7.36% |
| 2003-12-31 | $13.07 Billion | $3.75 Billion | 0.287x | -26.93% |
| 2002-12-31 | $10.66 Billion | $4.18 Billion | 0.392x | -0.38% |
| 2001-12-31 | $9.06 Billion | $3.57 Billion | 0.394x | +8.87% |
| 2000-12-31 | $8.57 Billion | $3.10 Billion | 0.362x | -8.56% |
| 1999-12-31 | $7.43 Billion | $2.94 Billion | 0.395x | -17.32% |
| 1998-12-31 | $5.71 Billion | $2.73 Billion | 0.478x | -9.05% |
| 1997-12-31 | $5.00 Billion | $2.63 Billion | 0.526x | +6.42% |
| 1996-12-31 | $4.82 Billion | $2.38 Billion | 0.494x | +10.55% |
| 1995-12-31 | $4.40 Billion | $1.97 Billion | 0.447x | -18.17% |
| 1994-12-31 | $4.05 Billion | $2.21 Billion | 0.546x | +8.70% |
| 1993-12-31 | $3.67 Billion | $1.85 Billion | 0.503x | +21.14% |
| 1992-12-31 | $3.35 Billion | $1.39 Billion | 0.415x | -8.56% |
| 1991-12-31 | $3.20 Billion | $1.45 Billion | 0.454x | +7.05% |
| 1990-12-31 | $2.83 Billion | $1.20 Billion | 0.424x | +20.37% |
| 1989-12-31 | $2.73 Billion | $959.90 Million | 0.352x | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more